The rapid inactivation of ANO1 is reasonably well understood [42,49] and raises the question as to whether direct pharmacological activation of ANO1 by the synthetical compound ETX001 (called ETD-002 in the clinical trial) can be successful in restoring Cl secretion in the airways of CF patients [50,51]. The gene discussed is ANO1; the disease is cystic fibrosis.